Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - black snake antivenom, quantity: 18000 u - injection, concentrated - excipient ingredients: sodium chloride; phenol; water for injections - for the treatment of patients who exhibit manifestations of systemic envenoming following a bite by a king brown or mulga snake. although the antivenom is effective in the management of patients who are bitten by other members of the genus pseudechis, including the red-bellied or common black snake, tiger snake antivenom is the preferred treatment.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - red-back spider antivenom, quantity: 500 u - injection, solution - excipient ingredients: phenol; water for injections; sodium chloride - for the treatment of patients who exhibit manifestations of systemic envenoming following a bite by a red back spider.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - stonefish antivenom, quantity: 2000 u - injection, solution - excipient ingredients: phenol; sodium chloride; water for injections - for the treatment of patients who exhibit manifestations of systemic envenoming by stonefish antivenom.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - safinamide mesilate, quantity: 65.88 mg (equivalent: safinamide, qty 50 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; colour; hypromellose; macrogol 6000 - xadago is indicated for the treatment of adult patients with fluctuating idiopathic parkinson?s disease (pd) as add-on therapy to a regimen that includes levodopa (l-dopa)

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - safinamide mesilate, quantity: 131.76 mg (equivalent: safinamide, qty 100 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; crospovidone; colour; hypromellose; macrogol 6000 - xadago is indicated for the treatment of adult patients with fluctuating idiopathic parkinson?s disease (pd) as add-on therapy to a regimen that includes levodopa (l-dopa)

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - box jellyfish antivenom, quantity: 20000 u - injection, solution - excipient ingredients: phenol; sodium chloride; water for injections - for the treatment of patients who exhibit manifestations of systemic envenoming or who have extensive local involvement causing extreme pain which does not respond to routine analgesic therapy.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - funnel-web spider antivenom, quantity: 125 u - injection, powder for - excipient ingredients: monobasic sodium phosphate; dibasic sodium phosphate; sodium chloride; glycine - for the treatment of patients who exhibit manifestations of systemic envenoming following a bite by a funnel web spider.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - rabies virus, quantity: 2.5 iu - injection, powder for - excipient ingredients: monopotassium glutamate; trometamol; sodium chloride; disodium edetate; polygeline; sucrose - active immunisation against rabies virus, including a) pre-exposure immunisation b) post-exposure treatment following exposure to rabies virus.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - phleum pratense, quantity: 75000 sq-t - tablet - excipient ingredients: gelatin; mannitol; sodium hydroxide; purified water - grazax is indicated for disease modifying treatment of grass pollen (phleum pratense or allergens cross reacting with p. pratense) induced allergic rhinitis with or without conjunctivitis in adults, adolescents and children above the age of 5 years.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))); influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))); influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))); influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 (bvr-1b))) - suspension for injection - 60 mcg/0.5ml - active: influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))) influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))) influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))) influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 (bvr-1b))) excipient: calcium chloride dihydrate dibasic sodium phosphate monobasic potassium phosphate monobasic sodium phosphate potassium chloride sodium chloride water for injection - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. afluria quad vaccine is indicated for use in persons aged 3 years and over. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.